Walter Young, MD
Gastroenterology · Dallas, TXNPI 1356301055
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,130 of the $1,310 with a category attached, or 86.3%. 17 manufacturers reported payments, led by AbbVie at 27.1% of the total. That places this record below the midpoint for gastroenterology clinicians in TX, where the typical reported total is $3,104.
Across 61 payments — averaging $21.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$355
- Braintree Laboratories, Inc.$198
- Sanofi$105
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$98
- Merck$96
- Takeda Pharmaceuticals U.S.A., Inc.$86
- plus $370 from 11 others
What the payments were for
- Food & beverage$1,13086%
- Gifts$18014%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 21 | $355 |
| Braintree Laboratories, Inc. | 4 | $198 |
| Sanofi | 4 | $105 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $98 |
| Merck | 5 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $86 |
| Celltrion USA Inc. | 4 | $81 |
| Bristol Myers Squibb | 4 | $63 |
| Lucid Diagnostics Inc. | 1 | $46 |
| Regeneron Healthcare Solutions, Inc. | 2 | $43 |
| Lilly USA, LLC | 1 | $25 |
| Intercept Pharmaceuticals, Inc. | 1 | $24 |
| Pfizer | 1 | $21 |
| QOL Medical, LLC | 1 | $21 |
| Amgen | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Vivus LLC | 1 | $14 |
How this compares
$1,310 in reported general payments places this provider in the 30th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mesalamine ErMesalamine | 13 | $5,895 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 346 | $4,774 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 65 | $3,553 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 96 | $1,464 |
| Omeprazole | 46 | $870 |
| Ursodiol | 11 | $628 |
| Pantoprazole Sodium | 97 | $481 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Dallas
- John FordtranDallas$9.9M
- Michael BrownDallas$5.5M
- Parvez MantryDallas$958K
- Jay HortonDallas$326K
- Jacqueline O LearyDallas$157K
- Sami ArslanlarDallas$142K
- Amit DesaiDallas$71K
- Byron CryerDallas$68K
- Bincy AbrahamHouston$1.6M
- Mazen NoureddinHouston$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.